Core Insights - CalciMedica Inc. announced the acceptance of abstracts for presentations at two upcoming medical conferences, focusing on the Phase 2b CARPO trial of its lead product candidate Auxora™ for treating acute pancreatitis [1][2] Group 1: Presentation Details - The plenary presentation at the American Pancreatic Association (APA) 2024 Annual Meeting will be titled "Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS" and will be delivered by Prof. Robert Sutton [2] - The poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting will cover a randomized, double-blind, placebo-controlled dose-ranging study of Auxora in patients with acute pancreatitis and accompanying systemic inflammatory response syndrome (SIRS) [2] Group 2: Company Overview - CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases [3] - The company’s lead product candidate, Auxora™, has shown positive clinical results in multiple completed efficacy trials, including a Phase 2b trial (CARPO) for acute pancreatitis and a Phase 2 trial (CARDEA) for COVID pneumonia [3] - CalciMedica is also conducting ongoing trials for acute kidney disease and pediatric patients with asparaginase-induced pancreatic toxicity, with data expected in 2025 [3]
CalciMedica Announces Presentations at Upcoming Medical Meetings